The effects of continuous positive airway pressure and mandibular advancement therapy on metabolic outcomes of patients with mild obstructive sleep apnea: a randomized controlled study.

Abstract

Moderate and severe obstructive sleep apnea (OSA) have been independently associated with dyslipidemia. The results of metabolic improvement with continuous positive airway pressure (CPAP) have been controversial. Less evidence exists regarding this issue in mild OSA. A current treatment for mild OSA is mandibular advancement device (MAD) therapy, but its effectiveness on the metabolic profile needs to be compared with CPAP. The purpose of this study was to compare MAD vs CPAP vs no treatment on the metabolic profile during 6 and 12months of follow-up in patients with mild OSA. The inclusion criteria were patients with mild OSA, both genders, ages 18 to 65years, and body mass index (BMI) of <35Kg/m2. Patients were randomized in 3 groups (CPAP, MAD, and control). The evaluations included physical examination, metabolic profile, and full polysomnography at baseline, 6months, and 12months of follow-up. Seventy-nine patients with mild OSA were randomized in three treatment groups, with mean age (± SD) of 47 ± 9years, 54% men, and AHI 9.5 ± 2.9 events/h. MAD and CPAP reduced AHI at 6 and 12months compared to the control group. MAD adherence was higher than CPAP at 6 and 12months. Despite lower adherencecompared to MAD, CPAP was more effective in reducing total cholesterol over 12months (baseline 189.3 ± 60.2mg/dl to 173.4 ± 74.3mg/dl) and low-density lipoprotein cholesterol (LDL-c, baseline 112.8 ± 54.9mg/dl to 94.5 ± 67.4mg/dl). After 1year of treatment, CPAP was superior to MAD in reducing total cholesterol and LDL-c in patients with mild OSA.